Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
J L Binet
Index: Nouv. Rev. Fr. Hematol. 35(1) , 5-7, (1993)
Full Text: HTML
Abstract
The review of Phase II trials in patients treated by Fludarabine phosphate (Fludara I.V) has been demonstrated to have unequivocal benefit for some patients with Chronic Lymphocytic Leukemia (CLL) non Hodgkin lymphoma and macroglobulinemia. Comparison of Fludara I.V with other treatment regimens is now studied in randomised protocols for B and C stages of CLL.
Related Compounds
Related Articles:
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.
2015-01-01
[Cancer Chemother. Pharmacol. 75(1) , 67-75, (2015)]
Fludarabine phosphate in lymphoma: an important new therapeutic agent.
1996-01-01
[Cancer Treat. Res. 85 , 3-14, (1996)]
1993-01-01
[Cancer Treat. Res. 64 , 105-19, (1993)]
1991-01-01
[J. Clin. Oncol. 9(1) , 175-88, (1991)]
Metabolism and action of fludarabine phosphate.
1990-10-01
[Semin. Oncol. 17(5 Suppl 8) , 3-17, (1990)]